Öhrfelt, A;
Brinkmalm, A;
Dumurgier, J;
Zetterberg, H;
Bouaziz-Amar, E;
Hugon, J;
Paquet, C;
(2019)
A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer's disease.
Neuroscience
, 420
pp. 136-144.
10.1016/j.neuroscience.2018.11.038.
Preview |
Text
Zetterberg_1-s2.0-S0306452218307802-main.pdf Download (1MB) | Preview |
Abstract
Synaptic degeneration is central in Alzheimer's disease (AD) pathogenesis and biomarkers to monitor this pathophysiology in living patients are warranted. We developed a novel sandwich enzyme-linked immunosorbent assay (ELISA) for the measurement of the pre-synaptic protein SNAP-25 in cerebrospinal fluid (CSF) and evaluated it as a biomarker for AD. CSF samples included a pilot study consisting of AD (N=26) and controls (N=26), and two independent clinical cohorts of AD patients and controls. Cohort I included CSF samples from patients with dementia due to AD (N=17), patients with mild cognitive impairment (MCI) due to AD (N=5) and controls (N=17), and cohort II CSF samples from patients with dementia due to AD (N=24), patients with MCI due to AD (N=18) and controls (N=36). CSF levels of SNAP-25 were significantly increased in patients with AD compared with controls (P≤0.00001). In both clinical cohorts, CSF levels of SNAP-25 were significantly increased in patients with MCI due to AD (P<0.0001). SNAP-25 could differentiate dementia due to AD (N=41) from controls (N=52) and MCI due to AD (N=23) from controls (N=52) with areas under the curve of 0.967 (P<0.0001) and 0.948 (P<0.0001), respectively. CSF SNAP-25 is a promising AD biomarker that differentiates AD patients in different clinical stages of the disease from controls with excellent diagnostic accuracy. Future studies should address the specificity of the CSF SNAP-25 against common differential diagnoses to AD, as well as how the biomarker changes in response to treatment with disease-modifying drug candidates.
| Type: | Article |
|---|---|
| Title: | A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer's disease |
| Location: | United States |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.neuroscience.2018.11.038 |
| Publisher version: | https://doi.org/10.1016/j.neuroscience.2018.11.038 |
| Language: | English |
| Additional information: | Copyright © 2018 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Keywords: | Alzheimer’s disease, Biomarker, Cerebrospinal fluid, ELISA, Mild cognitive impairment, SNAP-25 |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10064190 |
Archive Staff Only
 |
View Item |
